Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
56
CHGCY Quote, Financials, Valuation and Earnings
Last price:
$27.06
Seasonality move
:
2.76%
Day range:
$25.40 - $27.46
52-week range:
$19.50 - $31.26
Dividend yield:
0%
P/E ratio:
32.60x
P/S ratio:
10.67x
P/B ratio:
6.79x
Volume:
89.1K
Avg. volume:
125.4K
1-year change:
16.92%
Market cap:
$86.9B
Revenue:
$7.7B
EPS (TTM):
$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | -1.44% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
$26.40 | -- | $86.9B | 32.60x | $0.19 | 0% | 10.67x |
|
HLOSF
Healios KK
|
$3.40 | -- | $392.4M | -- | $0.00 | 0% | 533.86x |
|
PPTDF
PeptiDream Inc.
|
$10.95 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.00 | -- | $452.5M | -- | $0.00 | 0% | 2.34x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.31 | $17.76 | $45.2B | 181.60x | $0.34 | 4.65% | 1.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
0.64% | -0.833 | 0.11% | 4.62x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.605 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
$1.6B | $1.2B | 20.71% | 20.83% | 53.77% | $422.1M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Chugai Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns CHGCY or HLOSF?
Healios KK has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.69.91% $0.23 $12.9B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is CHGCY or HLOSF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.567, which suggesting that the stock is 43.303% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 31.25% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than Healios KK quarterly revenues of $128.8K. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Healios KK's net income of $3.8M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.60x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 10.67x versus 533.86x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.10.67x 32.60x $2.3B $754.1M HLOSFHealios KK533.86x -- $128.8K $3.8M
-
Which has Higher Returns CHGCY or PPTDF?
PeptiDream Inc. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -25.38%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.69.91% $0.23 $12.9B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is CHGCY or PPTDF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.567, which suggesting that the stock is 43.303% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 31.25% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.60x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 10.67x versus 11.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.10.67x 32.60x $2.3B $754.1M PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns CHGCY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -24.76%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.69.91% $0.23 $12.9B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is CHGCY or SOLTF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.567, which suggesting that the stock is 43.303% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 31.25% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.60x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 10.67x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.10.67x 32.60x $2.3B $754.1M SOLTFNxera Pharma Co., Ltd.2.34x -- $45.8M -$11.3M
-
Which has Higher Returns CHGCY or STMM?
Stemcell Holdings, Inc. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of --. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.69.91% $0.23 $12.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is CHGCY or STMM More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.567, which suggesting that the stock is 43.303% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 31.25% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.60x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 10.67x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.10.67x 32.60x $2.3B $754.1M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns CHGCY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -1.05%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.69.91% $0.23 $12.9B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About CHGCY or TAK?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 23.91%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Chugai Pharmaceutical Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Chugai Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is CHGCY or TAK More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.567, which suggesting that the stock is 43.303% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, suggesting its less volatile than the S&P 500 by 97.262%.
-
Which is a Better Dividend Stock CHGCY or TAK?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.65% to investors and pays a quarterly dividend of $0.34 per share. Chugai Pharmaceutical Co., Ltd. pays 31.25% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios CHGCY or TAK?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.60x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 181.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 10.67x versus 1.54x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.10.67x 32.60x $2.3B $754.1M TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
